Open AccessAndrogen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer
Author(s) -
Rui Huang,
Jiguang Han,
Xiaoshuan Liang,
Shanshan Sun,
Yongdong Jiang,
Bo Xia,
Ming Niu,
Dalin Li,
Jian Zhang,
Shuo Wang,
Wei Wei,
Qing Liu,
Wei Zheng,
Guoqiang Zhang,
Yanni Song,
Da Panga
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000484300
Subject(s) - bicalutamide , androgen receptor , estrogen receptor , breast cancer , prostate cancer , cancer research , medicine , endocrinology , cancer , oncology
Little is known about the potential mechanism of action for androgen receptor (AR) targeting treatment in estrogen receptor (ER)-negative breast cancer. This study aimed to evaluate AR status and its prognosis in four breast cancer subtypes. Bicalutamide has been identified as an AR antagonist and used for treating AR+/ER- breast cancer in a phase II trial. Our studies will clarify its mechanism in breast cancer treatment.